PCVX · Company research
Vaxcyte, Inc. Common Stock (PCVX): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
23records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX) - Seeking Alpha | Vaxcyte: Vaccine Titan In The Making (NASDAQ:PCVX) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 19, 2026 | neutral | 0 | 0.6 |
| Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet | Vaxcyte (PCVX) has gained 12.8% over the past four weeks and Wall Street analysts project a mean price target of $117.3, indicating a potential 75.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet | Vaxcyte (PCVX) has gained 12.8% over the past four weeks and Wall Street analysts project a mean price target of $117.3, indicating a potential 75.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets can be misleading and should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 1 | 1 |
| Vaxcyte slides as recent $1.15 billion financing weighs on shares - Quiver Quantitative | Vaxcyte slides as recent $1.15 billion financing weighs on shares Quiver Quantitative | View source ↗ | Quiver Quantitative | Oct 13, 2026 | neutral | 0 | 0.6 |
| How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing - Stock Traders Daily | How Vaxcyte Inc. (PCVX) Affects Rotational Strategy Timing Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 13, 2026 | neutral | 0 | 0.6 |
| Vaxcyte (NasdaqGS:PCVX) Stock Forecast & Analyst Predictions - Simply Wall Street | Vaxcyte (NasdaqGS:PCVX) Stock Forecast & Analyst Predictions Simply Wall Street | View source ↗ | Simply Wall Street | Oct 12, 2026 | neutral | 0 | 0.6 |
| Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History - Yahoo! Finance Canada | Vaxcyte, Inc. (PCVX) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 10, 2026 | neutral | 0 | 0.6 |
| Vaxcyte Bolsters Capital Structure with New Offerings - The Globe and Mail | Vaxcyte Bolsters Capital Structure with New Offerings The Globe and Mail | View source ↗ | The Globe and Mail | Oct 10, 2026 | neutral | 0 | 0.6 |
| Vaxcyte (PCVX) Stock Soars As VAX-31 Data Smash Expectations - StocksToTrade | Vaxcyte (PCVX) Stock Soars As VAX-31 Data Smash Expectations StocksToTrade | View source ↗ | StocksToTrade | Oct 9, 2026 | neutral | 0 | 0.6 |
| Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes | Vaxcyte, a clinical-stage vaccine company, announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds: 7.4 million shares of common stock at $64.00 per share and $500 million in convertible senior notes due 2032 with a 1.50% interest rate. The company plans to use net proceeds to fund clinical development of VAX-31 (31-valent pneumococcal conjugate vaccine) programs, manufacturing scale-up, commercial preparations for potential U.S. adult launch, and general corporate purposes. The offerings are expected to close on October 9, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes | Vaxcyte, a clinical-stage vaccine company, announced pricing for concurrent public offerings totaling approximately $1 billion in gross proceeds: 7.4 million shares of common stock at $64.00 per share and $500 million in convertible senior notes due 2032 with a 1.50% interest rate. The company plans to use net proceeds to fund clinical development of VAX-31 (31-valent pneumococcal conjugate vaccine) programs, manufacturing scale-up, commercial preparations for potential U.S. adult launch, and general corporate purposes. The offerings are expected to close on October 9, 2026. | View source ↗ | GlobeNewswire Inc. | Oct 7, 2026 | bullish | 1 | 1 |
| Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? | Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.667 | 1 |
| Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains? | Novavax stock jumped 20.1% following renewed investor interest in vaccine stocks, triggered by pneumonia-related concerns in Russia and positive results from Vaxcyte's pneumococcal vaccine. The company benefits from COVID-19 vaccine approvals and a Sanofi partnership. However, Novavax faces declining revenues and continued quarterly losses, though earnings estimate revisions have improved significantly. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.667 | 1 |
| Stock Market Today, Oct. 5: Tech Momentum Lifts Nasdaq as Treasury Yields Surge | The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes. | View source ↗ | The Motley Fool | Oct 5, 2026 | bullish | 1 | 1 |
| Two proposed $500 million offerings could fund Vaxcyte vaccine trials and U.S. launch preparations. - Stock Titan | Two proposed $500 million offerings could fund Vaxcyte vaccine trials and U.S. launch preparations. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more - CNBC | Stocks making the biggest moves midday: Microsoft, SpaceX, Vaxcyte, Banco Bradesco, DraftKings & more CNBC | View source ↗ | CNBC | Oct 5, 2026 | neutral | 0 | 0.6 |
| Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market - Investor's Business Daily | Small Biotech Squares Up To Pfizer, Merck In $7 Billion Market Investor's Business Daily | View source ↗ | Investor's Business Daily | Oct 5, 2026 | neutral | 0 | 0.6 |
| Vaxcyte Stock Hits New 52-Week High - Here’s Why - Vaxcyte (NASDAQ:PCVX) - Benzinga | Vaxcyte Stock Hits New 52-Week High - Here’s Why - Vaxcyte (NASDAQ:PCVX) Benzinga | View source ↗ | Benzinga | Oct 5, 2026 | neutral | 0 | 0.6 |
| Vaxcyte PCVX Stock Heats Up Ahead OPUS-1 Data - StocksToTrade | Vaxcyte PCVX Stock Heats Up Ahead OPUS-1 Data StocksToTrade | View source ↗ | StocksToTrade | Oct 5, 2026 | neutral | 0 | 0.6 |
| Vaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial - Yahoo Finance | Vaxcyte Shares Rise 50% After VAX-31 Meets Primary Endpoints in Phase 3 Trial Yahoo Finance | View source ↗ | Yahoo Finance | Oct 5, 2026 | neutral | 0 | 0.6 |
| PCVX Stock Jumps As Traders Brace For OPUS-1 Catalyst - Timothy Sykes | PCVX Stock Jumps As Traders Brace For OPUS-1 Catalyst Timothy Sykes | View source ↗ | Timothy Sykes | Oct 5, 2026 | neutral | 0 | 0.6 |
| Guggenheim raises Vaxcyte stock price target on vaccine trial win - Investing.com | Guggenheim raises Vaxcyte stock price target on vaccine trial win Investing.com | View source ↗ | Investing.com | Oct 5, 2026 | neutral | 0 | 0.6 |
| PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case - Stocktwits | PCVX Stock Hits Fresh 52-Week High On Late-Stage Win In Adult Pneumonia Vaccine Race: Jefferies Says It Hit ‘Blue-Sky’ Case Stocktwits | View source ↗ | Stocktwits | Oct 5, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.